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The 81-bp region of the rpoB gene in 66 Rifr Mycobacterium tuberculosis isolates from China, Japan, Korea,
and Taiwan was analyzed. Twelve single-nucleotide substitutions in the rpoB gene were detected. The most
prevalent mutations were at Ser-531 (52%), Asp-516 (17%), and His-526 (11%). Mutations were not found in
seven (11%) of the isolates. Higher mutation rates in 50 Beijing family isolates were found than in other isolates
for mutations at Asp-516 (18 and 12.5%, respectively) and His-526 (12 and 6.3%, respectively). The different
rates of mutation may reflect the choice of rifamycin analogs.
Antibiotic resistance is a growing impediment to the control
of infectious diseases worldwide, and multidrug-resistant
(MDR) tuberculosis (TB) continues to be a serious part of this
problem, particularly in Asia and developing countries (6, 8).
In 1999, the World Health Organization reported that 80% of
all incident TB cases were found in 22 countries, with more
than half the cases occurring in five Southeast Asian countries,
followed by the Western Pacific region, which accounted for
1.96 million cases (7). These findings indicated that the con-
stant creation and increased circulation of MDR TB threatens
not only the countries of origin, but also other countries
through immigration.
Resistance to rifampin is one of the key components in
antituberculosis therapeutic regimens and is a primary marker
of MDR TB. The resistance to rifampin in most cases is due to
the genetic alterations in the rpoB gene, encoding the -sub-
unit of DNA-dependent RNA polymerase (10, 13, 18, 20, 28,
32). It was demonstrated that more than 90% of Mycobacte-
rium tuberculosis isolates with the rifampin-resistant (Rifr) phe-
notype possess single-nucleotide substitutions within an 81-bp
fragment, the so-called hot spot region, of the rpoB gene (24,
33). Similar information on the frequency of occurrence of
rpoB mutations among isolates from different geographic ori-
gins has accumulated in recent years (9, 11, 17, 22, 25–27, 29).
Our finding of M. tuberculosis Beijing family, a dominant
clone in China and neighboring countries in Asia, led to our
interest in tracking this distinct family and other isolates from
Asia (23, 30). Our recent data demonstrated that the Beijing
family dominates in Taiwan, Japan, Korea and China, where it
comprises 50 to 80% of all isolates (L. Qian, S. Yamamoto,
X. Zheng, and J. T. Douglas, Abstr. 101st Gen. Meet. Am. Soc.
Microbiol. 2001, p. 699, 2001). The Beijing family, as charac-
terized by spoligotyping, has nine spacers from lanes 35 to 43
and typically has 15 to 20 bands by IS6110 restriction fragment
length polymorphism. This family has similar DNA typing pat-
terns to the W family and W-like family, which also includes
fully susceptible and MDR isolates (2, 30).
Since acquisition of drug resistance could play a role in
contributing to the survival and spread of the Beijing family
and other M. tuberculosis isolates, we decided to investigate the
mutations in the rpoB gene among MDR TB isolates from four
Asian countries. A total of 66 rifampin-resistant (Rifr) MDR
TB isolates from China (n  25), Japan (n  3), Korea (n 
18), and Taiwan (n  20) were provided by the following
institutions: Central Reference Laboratory, National Tubercu-
losis Control Center, Beijing, China; Research Institute of
Tuberculosis, Japan Anti-Tuberculosis Association, Tokyo, Ja-
pan; Department of Microbiology, Yonsei University, Seoul,
Korea; and Taiwan Provincial Chronic Disease Control Bu-
reau, Taipei, Taiwan. Only one isolate per patient was tested.
Drug susceptibility testing was performed by the institutions
providing the samples, and resistance was determined by the
absolute concentration method. We previously classified the
isolates by spoligotyping as belonging to the nine-spacer sig-
nature of the Beijing family or as non-Beijing family isolates
and by the IS6110 DNA fingerprinting method (12, 23, 30).
Two oligonucleotide primers described by Williams et al.
(31), rpo105 (5-CGT GGA GGC GAT CAC ACC GCA GCA
GTT-3) and rpo293 (5-AGT GCG ACG GGT GCA CGT
CGC GGA CCT-3), were used to amplify a 215-bp fragment
of the rpoB gene containing the 81-bp hypervariable region.
The PCR product was sequenced using a Prism 377 automated
DNA sequencer (Applied Biosystems Inc., Foster City, Calif.).
Sequence data were assembled and analyzed by Clustal W
(http://www.clustalw.genome.ad.jp).
Although the genotype of rpoB, as a marker for MDR and
epidemiology of M. tuberculosis from different geographic re-
gions has been reported by several groups in the last decade (4,
5, 11, 12, 16, 17, 22, 25–29, 32), we have expanded this infor-
mation by adding data from China, Japan, Korea, and Taiwan.
Our analysis was also influenced by the dominance of the
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Beijing family in these regions (Qian et al., Abstr. 101st Gen.
Meet. Am. Soc. Microbiol. 2001). Twelve distinct mutations
affecting six codons in the 81-bp region, those encoding Gln-
513, Phe-514, Asp-516, His-526, Ser-531, and Leu-533, were
found among the 66 Rifr isolates (Table 1). None of the iso-
lates had more than one mutation. No novel mutations or
double or multiple mutations were exhibited beyond the 23
mutations described in earlier studies (33). The three most
prevalent mutations (accounting for 79% of the total) were
missense mutations at the positions Ser-531, His-526, and Asp-
516. This finding is comparable to the results of early studies
demonstrating the rpoB mutation frequencies in isolates from
the United States (13, 32), European and African countries
(28), Japan (21, 27), and Asian countries (11). A total of 58
isolates (88%) demonstrated a point (missense) mutation. A
3-nucleotide insertion, resulting in the addition of a phenylal-
anine residue between Phe-514 and Met-515, was found in one
Rifr isolate (2%). In addition, 7 (11%) of the 66 Rifr isolates
contained no mutations in the 215-bp sequenced region. It was
not possible to retest these isolates to reconfirm the resistance.
The frequency of mutations in isolates from the four coun-
tries is shown in Table 2. The most frequent mutations, re-
gardless of the geographic origins described by other Asian
investigators, occur at the codons encoding Ser-531 (42 to
53%), His-526 (17 to 34%), and Asp-516 (7 to 14%) (11, 14, 16,
21, 27). We found that the most prevalent mutation occurred
at the codon encoding Ser-531 (52%). However, our results
differed from the others in that in our study the mutation with
the second highest frequency was Asp-516 (17%) rather than
His-526 (8%). Earlier investigations revealed that mutant al-
leles particularly affecting either position 531 or 526 were as-
sociated with high-level resistance to rifampin (MIC  64
g/ml) (3, 21) and high-level cross-resistance to all rifamycins
(33), while mutation at the codon encoding Asp-516 was found
to cause medium-level rifampin and rifapentine resistance
(MIC  32 g/ml) but susceptibility to rifabutin. Based on
these reports, our finding might indicate that using different
analogs of rifamycin in different geographic regions results in a
selective pressure for mutations at different rpoB codons. For
example, it is known that rifabutin is the drug of choice for
treatment of tuberculosis in some areas of China.
A missense mutation at the codon encoding Gln-513 was
only observed in 4 (16%) of the 25 isolates from China. How-
ever, this mutation has been observed in isolates from other
countries, but at lower frequencies (11, 14, 28, 32). Two iso-
lates with the Leu533Pro missense mutation in this study were
from Taiwan but were also reported to be present at low
frequencies in isolates from the United States (28, 32) and the
Philippines (32). A single isolate with an insertion mutation,
adding a phenylalanine residue between positions 514 and 515,
was from Taiwan. Of the seven Rifr isolates showing no mu-
tation in the 81-bp region, four were from Taiwan; these made
up 20% of the Taiwanese isolates.
We compared the mutation profiles of the isolates from the
four regions, although we were limited to three isolates from
Japan. A genotype encoding the His526Tyr mutation was
found in one of the three isolates from Japan in our study. This
differed from previous findings that isolates from Japan did not
possess this mutation (21, 32). In addition, we observed that
less frequent mutations, at Gln-513, the 514-Phe insertion, and
at Leu-533, occurred mostly in isolates from China and Tai-
wan. In terms of resistance to other first-line drugs, earlier
reports showed that strains with the same rpoB genotype but
from different geographic locations had similar patterns of
drug resistance (19, 33). However, our data differed from the
earlier data in that the isolates with the same rpoB genotypes
tended to have the same resistance patterns to other drugs
(isoniazid, streptomycin, and ethambutol) only within their
geographic areas. In other words, the drug resistance patterns
were not shared among the isolates of different geographic
origin, although these isolates had the same rpoB genotypes
(data not shown). This is, again, probably the result of selective
pressure created by the implementation of different therapeu-
tic regimens and control policies in different regions.
Based on the recent information that the Beijing family has
emerged in many countries and regions where the drug resis-
tance of M. tuberculosis was high, it is thought that the Beijing
family might be associated with increased acquisition of drug
resistance (1, 8, 15). We found that the most frequent mutation
in both Beijing family and non-Beijing family isolates occurred
at Ser-531 (51 and 50%, respectively) (Table 3). However, the
Beijing family had higher mutation rates than the non-Beijing
isolates at Asp-516 (18 and 12.5%, respectively) and His-526
(12.0 and 6.3%, respectively). On the other hand, we observed
that the less frequently encountered mutations, at Leu-533 and
the Phe-514 insertion, were found only in the non-Beijing
TABLE 2. Frequency of rpoB mutations in 66 rifampin-resistant
M. tuberculosis isolates from four regions
Position of
mutation










514-Phe ins.a 1 (5.0)
Asp-516 4 (16.0) 4 (22.2) 3 (15.0)
His-526 1 (4.0) 1 (33.3) 3 (16.7) 2 (10.0)
Ser-531 14 (56.0) 2 (66.7) 10 (55.6) 8 (40.0)
Leu-533 2 (10.0)
None 2 (8.0) 1 (5.6) 4 (20.0)
a Phenylalanine insertion.
TABLE 1. Sequence analysis of rifampin-resistant M. tuberculosis







Gln513Leu 1 (1.5) China (1)
Gln513Lys 3 (4.5) China (3)
514-Phe ins.a 1 (1.5) Taiwan (1)
Asp516Ala 6 (9.1) China (1), Korea (3), Taiwan (2)
Asp516Tyr 5 (7.6) China (3), Korea (1), Taiwan (1)
His526Arg 1 (1.5) Taiwan (1)
His526Asn 1 (1.5) Korea (1)
His526Leu 2 (3.0) Korea (2)
His526Tyr 3 (4.5) China (1), Japan (1), Taiwan (1)
Ser531Gln 1 (1.5) Taiwan (1)
Ser531Leu 33 (50.0) China (14), Japan (2), Korea (10),
Taiwan (7)
Leu533Pro 2 (3.0) Taiwan (2)
None 7 (10.6) China (2), Korea (1), Taiwan (4)
a Phenylalanine insertion.
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family isolates. These findings, however, could be biased due to
the small number of the non-Beijing family isolates (n  16).
Limited data are available on the comparison of the Beijing
family with drug resistance rate in an area, mainly because the
numbers of Beijing family isolates and non-Beijing family iso-
lates were usually unequal in a selected area. However, we
found, in a recent study (J. Douglas, L. Qian, W. Guo, H.
Chien, M. Yu, and T. Ping, Abstr. 99th Gen. Meet. Am. Soc.
Microbiol. 1999, p. 438, 1999) that the Beijing family account-
ed for about 50% of isolates from Taiwan and that the drug
resistance rate in this family was significantly higher than that
in the non-Beijing family isolates (44 and 21%, respectively.)
Furthermore, a study of the M. tuberculosis W family, originally
isolated in New York City, where coinfection with M. tubercu-
losis and human immunodeficiency virus was high, revealed
that this family was highly related to MDR (2). Interestingly,
the W family has similar IS6110 fingerprinting patterns to
those of the Beijing family (2, 30), which strongly suggested
that the two families had a common ancestor in recent evolu-
tionary history. We expected that when resistance occurred in
the Beijing family, it would be with the rpoB mutations which
were related to high-level rifampin resistance as described in
previous reports (3, 33). However, our data demonstrated that
Beijing family and non-Beijing family isolates both acquire
high-level rifampin resistance (Ser-531 mutation) at similar fre-
quencies (52 and 50%, respectively), although differences were
observed in gaining the secondary mutations (His-526 and Asp-
516), with the Beijing family showing higher frequencies.
In summary, our data on rpoB mutation frequencies in iso-
lates from the four countries or regions supported the common
notion that rifampin resistance genotypes with mutations
at critical codons, i.e., those encoding Ser-531, His526 and
Asp516, were the most frequently found in M. tuberculosis
populations regardless of geographic origin. Trend of muta-
tions on rpoB appeared to be independent of their spoligotyp-
ing patterns. The Beijing family, which obviously had certain
selective advantages in these geographic regions, did not show
significant differences in frequency of occurrence of the most
common mutations in rpoB compared with isolates of non-
Beijing family genotypes. Regional differences in the selection
of mutations may be associated with the types of treatment and
choice of rifamycin analogs.
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